ArticleMedicine2026
Role of uridine phosphorylase 1 in cancer: A comprehensive pan-cancer analysis highlighting its prognostic and therapeutic potential.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- UPP1 in Cancer: Context-Dependent Roles in Metabolic Adaptation and Treatment Response.Current issues in molecular biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uridine phosphorylase 1 (UPP1) is implicated in numerous cancers, yet lacks comprehensive evaluation across cancer types. This pan-cancer study aims to elucidate UPP1's roles and establish its potential as a biomarker and therapeutic target. This study analyzes the expression, genetic alterations, DNA methylation, and prognostic significance of UPP1 across 33 cancer types using multiple cancer genomics databases. We utilized databases such as TIMER, GEPIA, UALCAN, cBioPortal, and Kaplan-Meier Plotter to conduct a systematic analysis of UPP1 involving gene expression, genetic alteration patterns, promoter methylation, and survival impact in various cancers. UPP1 showed high expression in 19 out of 33 cancers and was down-regulated in 4. Notably, high UPP1 expression was associated with poor prognosis in 8 cancer types (OS: hazard ratios >1, P <.05). The primary genetic alteration was amplification. Promoter methylation of UPP1 varied significantly across cancers, correlating inversely with expression levels. UPP1 expression also correlated significantly with tumor mutational burden and microsatellite instability (MSI) across multiple cancers and was linked to immune cell infiltration. UPP1 serves as a significant oncogenic factor in various cancers, highlighting its value as a prognostic biomarker and a potential therapeutic target. This study lays a foundation for further exploration of UPP1's mechanisms and therapeutic applications in oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.